DMUC4064A治疗铂耐药卵巢癌的I期剂量递增研究
该开放标签I期研究评估DMUC4064A在铂耐药卵巢癌患者中的安全性、药代动力学和初步活性。
要点
- DMUC4064A在铂耐药卵巢癌中耐受性可接受,RP2D为5.2 mg/kg。
- 25%患者确认客观缓解,临床获益率42%,中位PFS 3.9个月。
- 常见不良事件包括疲劳、恶心、腹痛、便秘、视物模糊、腹泻和贫血,40%患者出现眼毒性。
核心结论
- DMUC4064A在铂耐药卵巢癌中显示出可耐受的安全性和令人鼓舞的疗效。
主要发现
- 未达到最大耐受剂量,基于总体耐受性确定RP2D为5.2 mg/kg。
- 16例(25%)患者确认客观部分缓解(PR或CR),起始于≥3.2 mg/kg剂量水平;23例(35%)最佳缓解为PR或CR。
- 总体临床获益率为42%(27例最佳缓解为确认或未确认的CR、PR或持续≥6个月的SD)。
- 在54例MUC16免疫组化高评分患者中,临床获益率为46%(25例)。
关键数值与推荐
- RP2D为5.2 mg/kg,每3周给药。
- acMMAE暴露呈剂量比例,半衰期约6天。
- 确认客观缓解率25%,总体临床获益率42%,MUC16高评分患者临床获益率46%。
- 中位无进展生存期3.9个月。
临床怎么用
- DMUC4064A每3周5.2 mg/kg可作为铂耐药卵巢癌的潜在治疗选择,需关注眼毒性等不良事件。
局限性
- 本研究为I期开放标签剂量递增研究,样本量有限,疗效需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: MUC16 is overexpressed in the majority of human epithelial ovarian cancers (OC). DMUC4064A is a humanized anti-MUC16 monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E. This trial assessed the safety, tolerability, pharmacokinetics, and preliminary activity of DMUC4064A in patients with platinum-resistant OC. METHODS: DMUC4064A was administered once every 3 weeks to patients in 1.0-5.6 mg/kg dose escalation cohorts, followed by cohort expansion at the recommended Phase II dose (RP2D). RESULTS: Sixty-five patients were enrolled and received a median of 5 cycles (range 1-20) of DMUC4064A. The maximum tolerated dose was not reached; 5.2 mg/kg was the RP2D based on the overall tolerability profile. The most common adverse events were fatigue, nausea, abdominal pain, constipation, blurred vision, diarrhea, and anemia. Sixteen patients (25%) experienced related grade ≥ 3 toxicities. Twenty-six patients (40%) experienced ocular toxicities. The exposure of acMMAE was dose proportional, with a half-life of ~6 days. Sixteen patients (25%) experienced confirmed objective partial response (PR or CR) starting at ≥3.2 mg/kg dose levels, while 23 (35%) patients had best responses of PR or CR. Overall, the clinical benefit rate was 42% (27 patients with a best response [confirmed and unconfirmed] of CR, or PR or SD lasting ≥6 months). Among the 54 patients with high MUC16 immunohistochemistry scores, the clinical benefit rate was 46% (25 patients). Median progression-free survival was 3.9 months overall. CONCLUSIONS: In this Phase I study, DMUC4064A demonstrated a tolerable safety profile along with encouraging efficacy in the indication of platinum-resistant OC.
引用
- Liu J, Burris H, Wang JS, et al. An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2021. PMID: 34627611. doi:10.1016/j.ygyno.2021.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。